B. Le, Facteurs de risque de tuberculose et vaccination par, p.58

P. Brennan and H. Nikaido, The Envelope of Mycobacteria, Annual Review of Biochemistry, vol.64, issue.1, pp.29-63, 1995.
DOI : 10.1146/annurev.bi.64.070195.000333

S. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher et al., Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature, vol.25, issue.6685, pp.537-544, 1998.
DOI : 10.1093/nar/25.5.0955

J. Ernst, G. Trevejo-nunez, and N. Banaiee, Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis, Journal of Clinical Investigation, vol.117, issue.7, pp.1738-1783, 2007.
DOI : 10.1172/JCI31810

G. Mahairas, P. Sabo, M. Hickey, D. Singh, and C. Stover, Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis., Journal of Bacteriology, vol.178, issue.5, pp.1274-82, 1996.
DOI : 10.1128/jb.178.5.1274-1282.1996

P. Andersen, M. Munk, J. Pollock, and T. Doherty, Specific immune-based diagnosis of tuberculosis, The Lancet, vol.356, issue.9235, pp.1099-104, 2000.
DOI : 10.1016/S0140-6736(00)02742-2

A. Pym, P. Brodin, R. Brosch, M. Huerre, and S. Cole, Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti, Molecular Microbiology, vol.232, issue.Suppl., pp.709-726, 2002.
DOI : 10.1016/S0140-6736(00)83505-9

K. Lewis, R. Liao, K. Guinn, M. Hickey, S. Smith et al., Mimics Bacille Calmette???Gu??rin Attenuation, The Journal of Infectious Diseases, vol.187, issue.1, pp.117-140, 2003.
DOI : 10.1086/345862

F. Denis and C. Perronne, Mycobacterium tuberculosis et mycobactéries atypiques 10 Global Tuberculosis Control Report, 2004.

D. Antoine, Les cas de tuberculose maladie déclarés en France en, Bulletin Epidémiologie Hebdomadaire, vol.24, 2007.

E. Nava-aguilera, N. Andersson, E. Harris, S. Mitchell, C. Hamel et al., Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis, Int J Tuberc Lung Dis, vol.13, issue.1, pp.17-26, 2009.

B. Khan, P. Ahmed, K. Ullah, C. Hussain, I. Hussain et al., Frequency of tuberculosis in haematological malignancies and stem cell transplant recipients, J Coll Physicians, 2005.

G. Maartens, P. Willcox, and S. Benatar, Miliary tuberculosis: Rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults, The American Journal of Medicine, vol.89, issue.3, pp.291-297, 1990.
DOI : 10.1016/0002-9343(90)90340-J

H. Al-jahdali, K. Al-zahrani, P. Amene, Z. Memish, A. Shimemeri et al., Clinical aspects of miliary tuberculosis in Saudi adults, Int J Tuberc Lung Dis, vol.4, issue.3, pp.252-257, 2000.

O. Gonzalez, G. Adams, L. Teeter, T. Bui, J. Musser et al., Extra-pulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis, Int J Tuberc Lung Dis, 2003.

Z. Yang, Y. Kong, F. Wilson, B. Foxman, A. Fowler et al., Identification of Risk Factors for Extrapulmonary Tuberculosis, Clinical Infectious Diseases, vol.4, issue.2, pp.199-205, 2004.
DOI : 10.1016/S0962-8479(96)90110-0

J. Lin, C. Lai, Y. Chen, S. Lee, S. Tsai et al., Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis, Int J Tuberc Lung Dis, vol.13, issue.5, pp.620-625, 2009.

. Haute-autorité-de-santé, Guide ? Affection de longue durée Tuberculose < http

H. Blumberg, W. Burman, R. Chaisson, C. Daley, S. Etkind et al., Infectious Diseases Society of America: treatment of tuberculosis, Centers for Disease Control and Prevention Am J Respir Crit Care Med Feb, vol.15167, issue.4, pp.603-62, 2003.

C. Billy and D. Levy-bruhl, BCG vaccine and place of tuberculin skin test in 2006], Rev Med Interne, 2007.

L. Rodrigues, V. Diwan, and J. Wheeler, Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis, International Journal of Epidemiology, vol.22, issue.6, pp.1154-1162, 1993.
DOI : 10.1093/ije/22.6.1154

G. Colditz, T. Brewer, C. Berkey, M. Wilson, E. Burdick et al., Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature, JAMA: The Journal of the American Medical Association, vol.271, issue.9, pp.698-702, 1994.
DOI : 10.1001/jama.271.9.698

H. Al-jahdali, Z. Memish, and D. Menzies, The utility and interpretation of tuberculin skin tests in the Middle East, American Journal of Infection Control, vol.33, issue.3, pp.151-157, 2005.
DOI : 10.1016/j.ajic.2005.01.005

M. Pai, A. Zwerling, and D. Menzies, Systematic Review: T-Cell???based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update, Annals of Internal Medicine, vol.149, issue.3, pp.177-84, 2008.
DOI : 10.7326/0003-4819-149-3-200808050-00241

M. Farhat, C. Greenaway, M. Pai, and D. Menzies, False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?, Int J Tuberc Lung Dis, vol.10, issue.11, pp.1192-204, 2006.

S. Landi, M. Ashley, and S. Grzybowski, Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination, Can Med Assoc J, vol.97, issue.5, pp.222-227, 1967.

I. Ildirim, M. Hacimustafaoglu, and B. Ediz, Correlation of tuberculin induration with the number of Bacillus Calmette-Gu??rin vaccines, The Pediatric Infectious Disease Journal, vol.14, issue.12, pp.1060-1063, 1995.
DOI : 10.1097/00006454-199512000-00006

M. Ashley and C. Siebenmann, Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts, Can Med Assoc J, vol.97, issue.22, pp.1335-1344, 1967.

J. Streeton, N. Desem, and S. Jones, Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection, Int J Tuberc Lung Dis, vol.2, issue.6, pp.443-50, 1998.

I. Brock, M. Munk, A. Kok-jensen, and P. Andersen, Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10, Int J Tuberc Lung Dis, vol.5, issue.5, pp.462-469, 2001.

H. Mahomed, E. Hughes, T. Hawkridge, D. Minnies, E. Simon et al., Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection, Int J Tuberc Lung Dis, vol.10, issue.3, pp.310-316, 2006.

A. Lalvani, A. Pathan, H. Durkan, K. Wilkinson, A. Whelan et al., Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells, The Lancet, vol.357, issue.9273, pp.2017-2038, 2001.
DOI : 10.1016/S0140-6736(00)05115-1

T. Meier, H. Eulenbruch, P. Wrighton-smith, G. Enders, and T. Regnath, Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice, European Journal of Clinical Microbiology & Infectious Diseases, vol.40, issue.8, pp.529-565, 2005.
DOI : 10.4049/jimmunol.167.9.5217

R. Van-zyl-smit, A. Zwerling, K. Dheda, and M. Pai, Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review, PLoS ONE, vol.137, issue.12, p.8517, 2009.
DOI : 10.1371/journal.pone.0008517.t002

A. Veerapathran, R. Joshi, K. Goswami, S. Dogra, E. Moodie et al., T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data, PLoS ONE, vol.13, issue.17, p.1850, 2008.
DOI : 10.1371/journal.pone.0001850.t004

R. Zyl-smit, M. Pai, K. Peprah, R. Meldau, J. Kieck et al., Within-Subject Variability and Boosting of T-Cell Interferon-?? Responses after Tuberculin Skin Testing, American Journal of Respiratory and Critical Care Medicine, vol.180, issue.1, pp.49-58, 2009.
DOI : 10.1164/rccm.200701-084OC

A. Detjen, L. Loebenberg, H. Grewal, K. Stanley, A. Gutschmidt et al., Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol, 2009.

R. Belknap, J. Kelahar, K. Wall, C. Daley, and N. Schluger, Diagnosis of Latent Tuberculosis Infection in U.S. Health Care Workers: Reproducibility, Repeatability and 6 Month Follow-Up with Interferon-gamma Release Assays (IGRAs)., C25. DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS, p.4101, 2009.
DOI : 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A4101

W. Franken, S. Thijsen, R. Wolterbeek, J. Bouwman, H. Bannoudi et al., Variation in T- SPOT.TB spot interpretation between independent observers from different laboratories. Clin Vaccine Immunol, pp.1439-1481, 2009.

. 50-direction-générale-de-la-santé, N. Circulaire, . Dgs, and . Sd5c, relative à la pratique de la vaccination par le vaccin antituberculeux BCG, et à la pratique des tests tuberculiniques, 2004.

C. Supérieur-d-'hygiène-publique-de-france, Calendrier vaccinal 2006 : avis du Conseil Supérieur d'Hygiène Publique de France (section des maladies transmissibles). 19 mai, BEH, pp.29-30, 2006.

M. Mazurek, J. Jereb, A. Vernon, P. Lobue, S. Goldberg et al., Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection -United States, MMWR Recomm Rep, vol.59, issue.5, pp.1-25, 2010.

G. Comstock, How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis, pp.847-50, 1999.

M. Steele, R. Burk, and R. Desprez, Toxic hepatitis with isoniazid and rifampin. A meta-analysis

J. Ena and V. Valls, Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis, Clinical Infectious Diseases, vol.272, issue.2, pp.670-676, 2005.
DOI : 10.1001/jama.1994.03520020051014

R. Jasmer, D. Snyder, D. Chin, P. Hopewell, S. Cuthbert et al., Twelve Months of Isoniazid Compared with Four Months of Isoniazid and Rifampin for Persons with Radiographic Evidence of Previous Tuberculosis, American Journal of Respiratory and Critical Care Medicine, vol.104, issue.5, pp.1648-52, 2000.
DOI : 10.1164/ajrccm.160.2.9808039

L. Mcneill, M. Allen, C. Estrada, and P. Cook, Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent Tuberculosis, Chest, vol.123, issue.1, pp.102-108, 2003.
DOI : 10.1378/chest.123.1.102

K. Ijaz, J. Jereb, L. Lambert, W. Bower, P. Spradling et al., Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis Infection, Clinical Infectious Diseases, vol.38, issue.1
DOI : 10.1086/444463

S. Kaufmann, How can immunology contribute to the control of tuberculosis?, Nature Reviews Immunology, vol.97, issue.1, pp.20-30, 2001.
DOI : 10.1073/pnas.250480397

H. Liote, Tuberculose, agents anti-TNF et autres immunosuppresseurs??: ??volution des strat??gies de pr??vention, Revue des Maladies Respiratoires, vol.25, issue.10, pp.1237-1286, 2008.
DOI : 10.1016/S0761-8425(08)75089-7

W. Hanekom, B. Abel, and T. Scriba, Immunological protection against tuberculosis, S Afr Med J, 2007.

T. Ottenhoff, D. Kumararatne, and J. Casanova, Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria, Immunology Today, vol.19, issue.11, pp.491-495, 1998.
DOI : 10.1016/S0167-5699(98)01321-8

A. Cooper, D. Dalton, T. Stewart, J. Griffin, D. Russell et al., Disseminated tuberculosis in interferon gamma gene-disrupted mice, Journal of Experimental Medicine, vol.178, issue.6, pp.2243-2250, 1993.
DOI : 10.1084/jem.178.6.2243

H. Wajant, K. Pfizenmaier, and P. Scheurich, Tumor necrosis factor signaling, Cell Death and Differentiation, vol.10, issue.1, 2003.
DOI : 10.1038/sj.cdd.4401189

M. Gardam, E. Keystone, R. Menzies, S. Manners, E. Skamene et al., Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, The Lancet Infectious Diseases, vol.3, issue.3, pp.148-55, 2003.
DOI : 10.1016/S1473-3099(03)00545-0

S. Stenger, Immunological control of tuberculosis: role of tumour necrosis factor and more, Annals of the Rheumatic Diseases, vol.64, issue.suppl_4, pp.24-32, 2005.
DOI : 10.1136/ard.2005.042531

S. Stenger, Immunological control of tuberculosis: role of tumour necrosis factor and more, Annals of the Rheumatic Diseases, vol.64, issue.suppl_4, pp.24-32, 2005.
DOI : 10.1136/ard.2005.042531

J. Flynn, M. Goldstein, J. Chan, K. Triebold, K. Pfeffer et al., Tumor necrosis factor-?? is required in the protective immune response against mycobacterium tuberculosis in mice, Immunity, vol.2, issue.6, pp.561-72, 1995.
DOI : 10.1016/1074-7613(95)90001-2

V. Mohan, C. Scanga, K. Yu, H. Scott, K. Tanaka et al., Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology, Infection and Immunity, vol.69, issue.3, pp.1847-55, 2001.
DOI : 10.1128/IAI.69.3.1847-1855.2001

H. Bruns, C. Meinken, P. Schauenberg, G. Harter, P. Kern et al., Anti-TNF immunotherapy reduces CD8+ T cell???mediated antimicrobial activity against Mycobacterium tuberculosis in humans, Journal of Clinical Investigation, vol.119, issue.5, pp.1167-77, 2009.
DOI : 10.1172/JCI38482

O. Saliu, C. Sofer, D. Stein, S. Schwander, and R. Wallis, Tumor???Necrosis???Factor Blockers: Differential Effects on Mycobacterial Immunity, The Journal of Infectious Diseases, vol.194, issue.4, pp.486-92, 2006.
DOI : 10.1086/505430

A. Giardina, A. Accardo-palumbo, F. Ciccia, A. Ferrante, A. Principato et al., Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? Reumatismo, pp.21-27, 2009.

L. Carmona, C. Hernandez-garcia, C. Vadillo, E. Pato, A. Balsa et al., Increased risk of tuberculosis in patients with rheumatoid arthritis, J Rheumatol, vol.30, issue.7, pp.1436-1445, 2003.

S. Seong, C. Choi, J. Woo, K. Bae, C. Joung et al., Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers, J Rheumatol, vol.34, issue.4, pp.706-717, 2007.

H. Ho, M. Lin, K. Yu, C. Wang, Y. Wu et al., Pulmonary Tuberculosis and Disease-Related Pulmonary Apical Fibrosis in Ankylosing Spondylitis, The Journal of Rheumatology, vol.36, issue.2, pp.355-60, 2009.
DOI : 10.3899/jrheum.080569

S. Jick, E. Lieberman, M. Rahman, and H. Choi, Glucocorticoid use, other associated factors, and the risk of tuberculosis, Arthritis & Rheumatism, vol.362, issue.1, pp.19-26, 2006.
DOI : 10.7326/0003-4819-84-3-304

P. Brassard, A. Lowe, S. Bernatsky, A. Kezouh, and S. Suissa, Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum, pp.300-304, 2009.

P. Brassard, A. Kezouh, and S. Suissa, Antirheumatic Drugs and the Risk of Tuberculosis, Clinical Infectious Diseases, vol.52, issue.4, pp.717-739, 2006.
DOI : 10.1002/art.20942

N. Martinez, O. , R. Noiseux, C. , C. Martin et al., Reactivation tuberculosis in a patient with anti-TNF-alpha treatment, The American Journal of Gastroenterology, vol.44, issue.4, 2001.
DOI : 10.1164/ajrccm/142.3.725

J. Gomez-reino, L. Carmona, V. Valverde, E. Mola, and M. Montero, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report, Arthritis & Rheumatism, vol.44, issue.Suppl 9, pp.2122-2129, 2003.
DOI : 10.1056/NEJM200107193450307

F. Wolfe, K. Michaud, J. Anderson, and K. Urbansky, Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum, Feb, vol.50, issue.2, pp.372-381, 2004.

R. Wallis, M. Broder, J. Wong, M. Hanson, and D. Beenhouwer, Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists, Clinical Infectious Diseases, vol.3, issue.1, pp.1261-1266, 2004.
DOI : 10.1007/BF02715694

URL : https://academic.oup.com/cid/article-pdf/38/9/1261/901630/38-9-1261.pdf

A. Mohan, T. Cote, J. Block, A. Manadan, J. Siegel et al., Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor, Clinical Infectious Diseases, vol.3, issue.3, pp.295-304, 2004.
DOI : 10.1016/S1473-3099(03)00545-0

B. Baldin, A. Dozol, A. Spreux, and R. Chichmanian, Tuberculosis and infliximab treatment. National surveillance from, Presse Med, pp.353-360, 2000.

J. Askling, C. Fored, L. Brandt, E. Baecklund, L. Bertilsson et al., Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden, Arthritis & Rheumatism, vol.63, issue.7
DOI : 10.1002/art.21137

F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille et al., Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry, Arthritis & Rheumatism, vol.18, issue.7, pp.1884-94, 2009.
DOI : 10.4049/jimmunol.168.7.3394

URL : https://hal.archives-ouvertes.fr/hal-00618680

W. Dixon, K. Hyrich, K. Watson, M. Lunt, J. Galloway et al., Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR), Annals of the Rheumatic Diseases, vol.69, issue.3, pp.522-530, 2010.
DOI : 10.1136/ard.2009.118935

H. Plessner, P. Lin, T. Kohno, J. Louie, D. Kirschner et al., Neutralization of Tumor Necrosis Factor (TNF) by Antibody but not TNF Receptor Fusion Molecule Exacerbates Chronic Murine Tuberculosis, The Journal of Infectious Diseases, vol.195, issue.11, pp.1643-50, 2007.
DOI : 10.1086/517519

O. Saliu, C. Sofer, D. Stein, S. Schwander, and R. Wallis, Tumor???Necrosis???Factor Blockers: Differential Effects on Mycobacterial Immunity, The Journal of Infectious Diseases, vol.194, issue.4, pp.486-92, 2006.
DOI : 10.1086/505430

R. Wallis, Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade, Arthritis & Rheumatism, vol.13, issue.suppl 3, pp.947-52, 2008.
DOI : 10.1164/ajrccm.162.4.9911106

L. Carmona, J. Gomez-reino, V. Rodriguez-valverde, D. Montero, E. Pascual-gomez et al., Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis & Rheumatism, vol.75, issue.6, pp.1766-72, 2005.
DOI : 10.1164/ajrccm.159.1.9807020

P. Kavanagh, J. Gilmartin, O. Donnell, J. , O. Flanagan et al., Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee, Ir Med J, vol.101, issue.1, pp.6-7, 2008.

C. Beglinger, J. Dudler, C. Mottet, L. Nicod, F. Seibold et al., Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy, Swiss Med Wkly, vol.137, pp.43-44620, 2007.

I. Solovic, M. Sester, J. Gomez-reino, H. Rieder, S. Ehlers et al., The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement, Eur Respir J

L. Sichletidis, L. Settas, D. Spyratos, D. Chloros, and D. Patakas, Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis, Int J Tuberc Lung Dis, vol.10, issue.10, pp.1127-1159, 2006.

A. Raval, G. Akhavan-toyserkani, A. Brinker, and M. Avigan, Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med, pp.699-702, 2007.

M. Bray, C. Poulain, M. Dougados, and L. Gossec, Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment, Joint Bone Spine, vol.77, issue.2, pp.135-176, 2010.
DOI : 10.1016/j.jbspin.2009.10.012

D. Van-der-heijde, M. Van-'t-hof, P. Van-riel, L. Theunisse, E. Lubberts et al., Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score., Annals of the Rheumatic Diseases, vol.49, issue.11, pp.916-936, 1990.
DOI : 10.1136/ard.49.11.916

S. Garrett, T. Jenkinson, L. Kennedy, H. Whitelock, P. Gaisford et al., A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index, J Rheumatol, vol.21, issue.12, pp.2286-91, 1994.

J. Beytout, F. Denis, and F. Allaert, Description du statut vaccinal de la population adulte fran??aise, M??decine et Maladies Infectieuses, vol.32, issue.12, pp.678-88, 2002.
DOI : 10.1016/S0399-077X(02)00455-9

J. Rey, H. Delolme, and P. Gillois, Couverture vaccinale des jeunes hommes à l'arrivée au service national, BEH, vol.30, pp.133-168, 1994.

D. Ponce-de-leon, E. Acevedo-vasquez, S. Alvizuri, C. Gutierrez, M. Cucho et al., Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population, J Rheumatol, vol.35, issue.5, pp.776-81, 2008.

G. Matulis, P. Juni, P. Villiger, and S. Gadola, Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon ?? assay, Annals of the Rheumatic Diseases, vol.67, issue.1, pp.84-90, 2008.
DOI : 10.1136/ard.2007.070789

D. Ponce-de-leon, E. Acevedo-vasquez, A. Sanchez-torres, M. Cucho, J. Alfaro et al., Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis, Annals of the Rheumatic Diseases, vol.64, issue.9, pp.1360-1361, 2005.
DOI : 10.1136/ard.2004.029041

I. Koker, O. Pamuk, C. Karlikaya, N. Tuncbilek, and N. Cakir, A low prevalance of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings, Clin Exp Rheumatol, vol.25, issue.1, pp.54-63, 2007.

I. Sezer, H. Kocabas, M. Melikoglu, and M. Arman, Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy, Clinical Rheumatology, vol.1, issue.1, pp.53-60, 2009.
DOI : 10.1378/chest.68.3_Supplement.465

G. Panayi, J. Lanchbury, and G. Kingsley, The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis, Arthritis & Rheumatism, vol.141, issue.7, pp.729-764, 1992.
DOI : 10.1172/JCI105758

S. Tarlo, J. Day, P. Mann, and M. Day, Immediate Hypersensitivity to Tuberculin, vivo and in vitro studies, pp.33-40, 1977.
DOI : 10.1378/chest.71.1.33

M. Tamborenea, G. Tate, E. Mysler, J. Debonis, and A. Schijedman, Prevalence of positive ppd in a cohort of rheumatoid arthritis patients, Rheumatology International, vol.345, issue.3, pp.613-619
DOI : 10.1007/s00296-009-1027-z

D. Vassilopoulos, N. Stamoulis, E. Hadziyannis, and A. Archimandritis, Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment, J Rheumatol, 2008.

E. Kiray, O. Kasapcopur, V. Bas, A. Kamburoglu-goksel, K. Midilli et al., Purified Protein Derivative Response in Juvenile Idiopathic Arthritis, The Journal of Rheumatology, vol.36, issue.9, pp.2029-2061, 2009.
DOI : 10.3899/jrheum.090173

F. Bartalesi, S. Vicidomini, D. Goletti, C. Fiorelli, G. Fiori et al., QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases, European Respiratory Journal, vol.33, issue.3, pp.586-93, 2009.
DOI : 10.1183/09031936.00107608

Y. Kobashi, K. Mouri, S. Yagi, Y. Obase, N. Miyashita et al., Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis, Chest, vol.133, issue.5, pp.1196-202, 2008.
DOI : 10.1378/chest.07-1995

Y. Kobashi, K. Mouri, N. Miyashita, N. Okimoto, T. Matsushima et al., QuantiFERON TB-2G test for patients with active tuberculosis stratified by age groups, Scand J Infect Dis, vol.14, pp.1-6, 2009.

N. Douziech, I. Seres, A. Larbi, E. Szikszay, P. Roy et al., Modulation of human lymphocyte proliferative response with aging, Experimental Gerontology, vol.37, issue.2-3, pp.2-3369, 2002.
DOI : 10.1016/S0531-5565(01)00204-2

T. Stolzenburg, H. Binz, A. Fontana, M. Felder, and F. Wagenhaeuser, Impaired mitogen-induced interferon-gamma production in rheumatoid arthritis and related diseases, Scand J Immunol, 1988.

M. Seitz, I. Napierski, R. Augustin, W. Hunstein, and H. Kirchner, Reduced Production of Interferon Alpha and Interferon Gamma in Leukocyte Cultures from Patients with Active Rheumatoid Arthritis, Scandinavian Journal of Rheumatology, vol.130, issue.4, pp.257-62, 1987.
DOI : 10.1016/0090-1229(83)90027-2

T. Rowland, S. Mchugh, J. Deighton, R. Dearman, P. Ewan et al., Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells, Immunopharmacology, vol.40, issue.1, pp.11-20, 1998.
DOI : 10.1016/S0162-3109(98)00010-1

S. Agarwal, G. Marshall, and J. , Dexamethasone Promotes Type 2 Cytokine Production Primarily Through Inhibition of Type 1 Cytokines, Journal of Interferon & Cytokine Research, vol.21, issue.3, pp.147-55, 2001.
DOI : 10.1089/107999001750133159

R. Mortensen and H. Gewurz, Effects of C-reactive protein on the lymphoid system. II. Inhibition of mixed lymphocyte reactivity and generation of cytotoxic lymphocytes, J Immunol, 1976.

D. Baeten, N. Van-damme, F. Van-den-bosch, E. Kruithof, D. Vos et al., Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha, Annals of the Rheumatic Diseases, vol.60, issue.8, 2001.
DOI : 10.1136/ard.60.8.750

J. Smith, M. Barnes, D. Hong, M. Delay, R. Inman et al., Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation

M. Bocchino, A. Matarese, B. Bellofiore, P. Giacomelli, G. Santoro et al., Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment, Eur J Clin Microbiol Infect Dis, 2008.

N. Cobanoglu, U. Ozcelik, U. Kalyoncu, S. Ozen, S. Kiraz et al., Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers, Int J Tuberc Lung Dis, vol.11, issue.11, pp.1177-82, 2007.

R. Dinser, M. Fousse, U. Sester, K. Albrecht, M. Singh et al., Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay, Rheumatology, 2008.

S. Murakami, M. Takeno, Y. Kirino, M. Kobayashi, R. Watanabe et al., Screening of tuberculosis by interferon-?? assay before biologic therapy for rheumatoid arthritis, Tuberculosis, vol.89, issue.2, pp.136-177, 2009.
DOI : 10.1016/j.tube.2008.12.004

A. Pratt, K. Nicholl, and L. Kay, Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-?? agents: the Newcastle (UK) experience, Rheumatology, vol.46, issue.6, pp.1035-1041, 2007.
DOI : 10.1093/rheumatology/kem064

R. De and L. Thèse, La recherche de tuberculose latente est nécessaire avant l'introduction d'un traitement anti-TNF alpha

T. En-anglais, Diagnosis of latent tuberculosis in patients with chronic inflammatory arthritis prior TNF-blocker initiation: factors influencing results of an interferon gamma release assay

R. De, L. Thèse, and . Anglais, Use of interferon gamma release assay (IGRA) for the screening seems interesting but has not been validated. The aim of our study was to identify factors that may influence IGRA results in this situation. 590 patients with rheumatoid arthritis (49,8%), spondyloarthritis (45,9%) or other inflammatory rheumatism (4,2%) and eligible for biologic treatments have been consecutively recruited. A chest X-ray, a tuberculin skin test (TST) and an IGRA (T-SPOT.TB®) were performed for each patient. 78% were vaccinated with BCG. 21,2% of T-SPOT.TB® were positive, 63% negative and 15,8% indeterminate. Factors significantly associated with a positive test are older age, history of active tuberculosis and abnormal chest X-ray. Disease activity significantly influence indeterminate results rate, positively for rheumatoid arthritis, negatively for spondyloarthritis. There is no influence of BCG vaccination or treatment. The concordance rate between T-SPOT.TB® and TST is low (kappa =0,17), Screening for latent tuberculosis infection (LTBI) is mandatory before initiating TNF-alpha blocker treatment conclusion, T-SPOT.TB® is well correlated with most of the risk factors of tuberculosis and little influenced by chronic inflammatory arthritis or treatment. However, influence of disease activity on indeterminate results rate could be a problem

M. De-l-'ufr, tuberculose, polyarthrite rhumatoïde, spondylarthrite, test à la tuberculine, test de détection de la production d'interféron gamma INTITULÉ